bluuebunny/crossref_metadata_2025_split huggingface dataset:
Effect of Particle Size on Non-Isothermal Decomposition of Potassium Titanium Oxalate
Authors: Muraleedharan K. , Labeeb P. , Mujeeb V. M. Abdul , Aneesh M. H. , Devi T. Ganga , Kannan M. P. 
Published: December 2010

Abstract
The effect of particle size on the thermal decomposition of potassium titanium oxalate (PTO) has been studied using TG-DTA-DTG techniques in nitrogen atmosphere at different heating rates. The thermal decomposition of PTO undergoes through five stages, finally forming the stable potassium titanate. The theoretical mass loss data agree very well with experimental data for all stages of the thermal decomposition of PTO. The third thermal decomposition stage of PTO, the combined elimination of carbon monoxide and carbon dioxide, were subjected to kinetic analyses by a model free method, which is based on the isoconversional principle. We observed that both the onset and peak temperatures in DTA and DTG and the apparent activation energy are independent of particle size. The kinetic results indicate that the third thermal decomposition stage of PTO, the combined elimination of carbon monoxide and carbon dioxide, undergoes through a single step.
Genetic variants associated with persistent central obesity and the metabolic syndrome in a 12-year longitudinal study
Authors: Cheung Chloe Y Y , Tso Annette W K , Cheung Bernard M Y , Xu Aimin , Ong K L , Law Lawrence S C , Wat Nelson M S , Janus Edward D , Sham Pak C , Lam Karen S L 
Published: December 2010

ObjectiveCentral obesity predisposes to various cardiometabolic diseases and is a key component of the metabolic syndrome (MetS). We have previously demonstrated that three obesity-susceptible single nucleotide polymorphisms (SNPs), rs10938397 (GNPDA2), rs8050136 (FTO) and rs17782313 (MC4R), were associated with obesity and waist circumference in cross-sectional studies in the Chinese population. In this study, we investigate whether these SNPs could also predict the persistence of central obesity and MetS in subjects from the Hong Kong Cardiovascular Risk Factors Prevalence Study (CRISPS) cohort.Design and methodsWe genotyped these SNPs in i) 354 subjects with and 994 subjects without central obesity at both baseline and a 12-year follow-up, ii) 2214 subjects (816 cases and 1398 controls) in an MetS cross-sectional case–control study and iii) 225 subjects with and 1221 subjects without MetS at both baseline and the 12-year follow-up.ResultsBoth FTO rs8050136 (Page, sex-adjusted=0.019; odds ratio (OR) (95% confidence intervals (CI)): 1.35 (1.05, 1.73)) and GNPDA2 rs10938397 (Page, sex-adjusted=3×10−3; OR (95% CI): 1.34 (1.11, 1.63)) were significantly associated with persistent central obesity. GNPDA2 rs10938397 was also significantly associated with MetS (Page, sex-adjusted=0.011, OR (95% CI): 1.20 (1.04, 1.38)) in the case–control study. However, none of these SNPs showed an individual association with persistent MetS. In the combined genetic risk analyses for persistent central obesity and persistent MetS, the combined genetic risk score of the three SNPs showed an OR of 1.25 (95% CI: 1.10, 1.42; Page, sex-adjusted=4.92×10−3) and 1.19 (95% CI: 1.03, 1.38; Page, sex-adjusted=0.019) for each additional risk allele respectively.ConclusionThis study demonstrated that FTO and GNPDA2 variants predicted persistent central obesity in the Chinese population, further supporting their importance as obesity-susceptible genes.
Elülső mellkasfali deformitás Nuss szerinti rekonstrukciója fiatal felnőtteken és idősebb kamaszokon
Authors: Vágvölgyi Attila , Kocsis Ákos , Agócs László , Heiler Zoltán , Vadász Pál , Csekeő Attila 
Published: December 2010

Absztrakt
Közleményünkben pectus excavatum miatt 86 fiatal felnőttön Nuss-technikával végzett elülső mellkasfali korrekciós műtétek retrospektív elemzését végeztük el. Áttekintjük az eredményeket, az előforduló szövődményeket és azon módszereket, melyekkel a szövődmények valószínűsége csökkenthető, a műtéttechnikai részleteket is érintve. A betegek életkorát figyelembe véve értékeljük a Nuss-műtét felnőttkori alkalmazhatóságát. Az elmúlt 7 év alatt osztályunkon 86 betegen végeztünk minimálisan invazív elülső mellkasfali korrekciót. A betegek átlagéletkora 21,4 év volt. Súlyos intraoperatív szövődményt nem tapasztaltunk. Fémelmozdulást négy betegnél észleltünk, a 12, illetve 53 nappal a műtét után kialakuló elmozdulás ismételt Nuss-műtéttel megoldható volt. Egy lemezt a 13. posztoperatív napon helyi septicus szövődmény miatt, egyet pedig 14 hónappal a műtét után sterilen bekövetkező jelentős dislocatio miatt távolítottunk el. Egy beteg fájdalom miatt kérte a fém kivételét. Egy, az arteria mammaria oldalágából származó intraoperatív vérzést VATS technikával, egy tüdősérülés okozta légmellet mellkasi drainage-zsal oldottunk meg. A rekonstrukció eredménye tartós, a betegek több mint 90%-a elégedett és panaszmentes. Az évek folyamán a műtéti időtartamunk és az ápolási idő csökkent. A Nuss-műtétek biztonsággal és jó hosszú távú eredménnyel alkalmazhatók fiatal felnőttek pectus excavatum korrekciójára. A rövid hospitalizáció, kisebb műtéti fájdalom, a minimálisan invazív műtét csökkent időtartama jelenti a beavatkozás előnyeit. Fokozottabb rizikót a 30 év feletti életkor és a megelőző mellkasfali korrekció jelent.
Phase I Study of Pazopanib in Combination with Weekly Paclitaxel in Patients with Advanced Solid Tumors
Authors: Tan Antoinette R. , Dowlati Afshin , Jones Suzanne F. , Infante Jeffrey R. , Nishioka Jennifer , Fang Lei , Hodge Jeffrey P. , Gainer Shelby D. , Arumugham Thangam , Suttle A. Benjamin , Dar Mohammed M. , Lager Joanne J. , Burris Howard A. 
Published: December 2010

Abstract

Purpose.
To evaluate the maximum tolerated regimen (MTR), dose-limiting toxicities, and pharmacokinetics of pazopanib, an oral small-molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-Kit, in combination with paclitaxel.

Patients and Methods.
Pazopanib was given daily with weekly paclitaxel on days 1, 8, and 15 every 28 days. Dose levels of pazopanib (mg/day)/paclitaxel (mg/m2) were 400/15, 800/15, 800/50, and 800/80. An expanded cohort was enrolled at the MTR. Plasma samples were collected to evaluate the effect of pazopanib, an inhibitor of cytochrome P450 (CYP)3A4, on the pharmacokinetics of paclitaxel, a CYP3A4 and CYP2C8 substrate.

Results.
Of 26 enrolled patients, 17 were treated at the MTR of 800 mg pazopanib and 80 mg/m2 paclitaxel. Dose-limiting toxicities included a grade 3 abscess and grade 2 hyperbilirubinemia. Other toxicities included elevated liver transaminases and diarrhea. Six patients (23%) had partial responses and 15 patients (58%) had stable disease. Administration of 800 mg pazopanib resulted in a 14% lower paclitaxel clearance and a 31% higher paclitaxel maximal concentration than with administration of paclitaxel alone at 15, 50, and 80 mg/m2. At the MTR, coadministration of 800 mg pazopanib and 80 mg/m2 paclitaxel resulted in a 26% higher geometric mean paclitaxel area under the curve.

Conclusion.
Pazopanib, at a dose of 800 mg daily, can be safely combined with a therapeutic dose of paclitaxel at 80 mg/m2 when administered on days 1, 8, and 15, every 28 days. The observed greater plasma concentrations of paclitaxel given concurrently with pazopanib suggest that pazopanib is a weak inhibitor of CYP3A4 and CYP2C8.
Nonpalpable Breast Carcinomas: Long-Term Evaluation of 1,258 Cases
Authors: Veronesi Umberto , Luini Alberto , Botteri Edoardo , Zurrida Stefano , Monti Simonetta , Galimberti Viviana , Cassano Enrico , Latronico Antuono , Pizzamiglio Maria , Viale Giuseppe , Vezzoli Dario , Rotmensz Nicole , Musmeci Simona , Bassi Fabio , Burgoa Loredana , Maisonneuve Patrick , Paganelli Giovanni , Veronesi Paolo 
Published: December 2010

Abstract

Introduction.
In recent decades, a steady improvement in imaging diagnostics has been observed together with a rising adherence to regular clinical breast examinations. As a result, the detection of small clinically occult (nonpalpable) lesions has progressively increased. At present in our institution some 20% of the cases are treated when nonpalpable. The aim of the present study is to analyze the characteristics and prognosis of such tumors treated in a single institution.

Methods.
The analysis focused on 1,258 women who presented at the European Institute of Oncology with a primary clinically occult carcinoma between 2000 and 2006. All patients underwent radioguided occult lesion localization (ROLL), axillary dissection when appropriate, whole breast radiotherapy, or partial breast intraoperative irradiation and received tailored adjuvant systemic treatment.

Results.
Median age was 56 years. Imaging showed a breast nodule in half of the cases and a breast nodule accompanied by microcalcifications in 9%. Microcalcifications alone were present in 17.1% of the cases, whereas suspicious opacity, distortion, or thickening represented the remaining 24.6%. Most tumors were characterized by low proliferative rates (68.9%), positive estrogen receptors (92.3%), and non-overexpressed Her2/neu (91.3%). After a median follow-up of 60 months, we observed 19 local events (1.5%), 12 regional events (1%), and 20 distant metastases (1.6%). Five-year overall survival was 98.6%.

Conclusions.
Clinically occult (nonpalpable) carcinomas show very favorable prognostic features and high survival rates, showing the important role of modern imaging techniques.
The Utility of BRAF Testing in the Management of Papillary Thyroid Cancer
Authors: Melck Adrienne L. , Yip Linwah , Carty Sally E. 
Published: December 2010

AbstractOver the last decade, investigators have developed a clearer understanding of the genetic alterations underlying thyroid carcinogenesis. A number of biomarkers involved in the pathogenesis of differentiated thyroid cancer have undergone intensive study, not only for their role in tumorigenesis, but also for their potential utility as diagnostic and prognostic indicators and therapeutic targets. This review summarizes the current literature surrounding BRAF and its significance in thyroid cancer. Further, we discuss how molecular analysis can be integrated into management algorithms for thyroid nodules and papillary thyroid cancer. We also review what is known, to date, about the association of BRAF and papillary microcarcinoma as well as using targeted therapies for BRAF as adjuvant treatment for metastatic papillary thyroid cancer.
Breast Cancer and Pregnancy: Current Concepts in Diagnosis and Treatment
Authors: Litton Jennifer K. , Theriault Richard L. 
Published: December 2010

Abstract
The treatment of breast cancer diagnosed during pregnancy presents a challenging situation for the patient, family, and caregivers. Case series have demonstrated the efficacy and safety of using anthracycline-based chemotherapy during the second and third trimesters. Additionally, patients should be seen, evaluated, and treated in a multidisciplinary setting with facilitated communication among the medical oncologist, surgical oncologist, obstetrician, radiation oncologist, pathologist, and radiologist. This review details the available data regarding the diagnosis and management of the pregnant breast cancer patient.
Contribution to the knowledge of the infection with Acanthocephala of a predatory Antarctic ice-fish Chaenocephalus aceratus
Authors: Laskowski Zdzisław , Zdzitowiecki Krzysztof 
Published: December 2010

Contribution to the knowledge of the infection with Acanthocephala of a predatory Antarctic ice-fish Chaenocephalus aceratus
Adult females of a predatory fish, the blackfin icefish, Chaenocephalus aceratus examined at the South Shetland Islands and South Orkney Islands were by several orders of magnitude more infected with Acanthocephala than the males and immature females. Such phenomenon has not been observed in the neritic zone at South Georgia. Cystacanths of Corynosoma hamanni and Corynosoma pseudohamanni were the dominant parasites in Admiralty Bay, whereas Corynosoma bullosum was the dominant in the open sea off the South Shetland Islands and South Georgia, and in the sub-coastal waters off the South Orkney Islands. However, the dominance of C. bullosum was observed in several hosts in Admiralty Bay and the co-dominance of C. bullosum, C. hamanni, and C. pseudohamanni in one mature female in the neritic zone at the South Shetland Islands. Probably, these fish previously lived in the open sea. Cystacanths of Corynosoma arctocephali and Corynosoma shackletoni occurred in the fish in Admiralty Bay and off South Georgia. The former parasite was present also off the South Orkney Islands. One cystacanth of Andracantha baylisi was found off South Georgia. Two echinorhynchids, Aspersentis megarhynchus and Metacanthocephalus dalmori, occurred in the alimentary tracts of the fish caught in Admiralty Bay and one specimen of Echinorhynchus petrotschenkoi off the South Shetland Islands. The highest infection, amounting to 816 acanthocephalans, was found in a mature female in Admiralty Bay. One cystacanth of C. hamanni occurred in a single immature fish caught in the sub-coastal area off Deception Island.
Gα13 and Rho Mediate Endosomal Trafficking of CXCR4 into Rab11+ Vesicles upon Stromal Cell-Derived Factor-1 Stimulation
Authors: Kumar Ashok , Kremer Kimberly N. , Dominguez Daniel , Tadi Madhavi , Hedin Karen E. 
Published: December 2010

Abstract
CXCR4, like other G protein-coupled receptors, signals via heterotrimeric guanine nucleotide-binding proteins (G proteins) to regulate gene transcription, migration, development, growth, and transformation. We describe a formerly uncharacterized function of a G protein: a role in receptor trafficking. We previously showed that CXCR4 and the TCR physically associate and form a heterodimer upon stromal cell-derived factor-1 or CXCL12 (SDF-1) stimulation in human T cells to prolong ERK activation and, thereby, lead to gene upregulation and cytokine secretion. The CXCR4–TCR heterodimers occur on the cell surface and in an intracellular compartment in response to SDF-1. Neither the intracellular compartment to which the CXCR4–TCR heterodimers localize nor the mechanism for localization has been elucidated. In this article, we characterize molecular mechanisms required for postendocytic trafficking of CXCR4. Upon SDF-1 stimulation, CXCR4 localizes to Rab11+ vesicles, a recycling compartment near the microtubule organizing center and Golgi apparatus. This trafficking requires the CXCR4 C-terminal tail domain but not the CXCR4 ubiquitination sites. The TCR also constitutively localizes to this Rab11+ compartment. Trafficking of CXCR4 into the Rab11+, TCR-containing endosomes requires actin polymerization. Furthermore, inhibiting Rho activation or depleting Gα13 prevented trafficking of CXCR4 into the Rab11+ endosomes without hindering the ability of CXCR4 to endocytose. These results indicated that, upon SDF-1 treatment, Gα13 and Rho mediate the actin polymerization necessary for trafficking CXCR4 into the Rab11+, recycling endosomal compartment, which also contains constitutively recycling TCR and, thus, CXCR4–TCR heterodimers. To our knowledge, this is the first report of Gα13 as a mediator of receptor trafficking.
Biofeedback Certification Institute of America Educators Who Have Made a Difference
Authors: Shaffer Fred , Crawford Judy 
Published: December 2010

Abstract
The Biofeedback Certification Institute of America believes that the public has a right to efficacious treatment from competent certified biofeedback professionals who practice ethically and operate within the scope of their professions. This article is the first in a series that introduces the dedicated educators who have helped us succeed in our mission to protect the welfare of biofeedback consumers, to provide credibility to biofeedback practitioners, and to advance the field of biofeedback.
Integration of Neurofeedback in the Therapeutic Work With Torture and Trauma Survivors: A Case Study
Authors: Askovic Mirjana , Gould Deborah 
Published: December 2010

AbstractThis paper describes a case study of a 14-year-old African refugee boy who survived multiple traumas related to war, displacement, and deprivation. Traumatized from the age of 2, his presentation was primarily one of affect dysregulation. In order to address both the core hyperarousal and the unavailability of the necessary cortical and behavioral skills required to regulate affect, an approach was chosen that integrates neurofeedback (electroencephalographic biofeedback) and psychotherapy.We trust that the description of the process provides others with new practice options and an enthusiasm to expand in this direction.
Low Energy Neurofeedback System Treatment of an Acquired Brain Injury due to Sudden Cardiac Arrest
Authors: Harper Sara Hunt 
Published: December 2010

Abstract
There is confusion regarding whether to identify brain injuries as a traumatic brain injury, an acquired brain injury, or a combination of both. No matter what you call it, brain injuries are a major public health problem. This article demonstrates the power of the Low Energy Neurofeedback System, a form of electroencephalography biofeedback/neurofeedback, with a 71-year-old woman who had a sudden cardiac arrest and was without pulse or respiration for 8 to 10 minutes. NeuroField and hyperbaric oxygen therapy were added later on in the treatment process.
What Has Biofeedback Certification Institute of America Been up to?
Authors: Shaffer Fred , Crawford Judy 
Published: December 2010

Abstract
The Biofeedback Certification Institute of America (BCIA) board has actively involved our certificants in strategic planning designed to strengthen our advocacy for the issues that concern them, improve an already successful certification process, and identify initiatives that will add value and recognition to our credentials. This article details the exciting actions that we have taken to protect the welfare of biofeedback consumers, to provide credibility to biofeedback practitioners, and to advance the field of biofeedback.
Adding Value to Your Biofeedback Certification International Alliance (BCIA) Certification: A Q&A With the BCIA Board
Authors: Neblett Randy , Shaffer Fred , Crawford Judy 
Published: December 2010

Abstract
The Biofeedback Certification International Alliance (BCIA) receives tens of thousands of inquiries each year. Due to the many recent policy and product changes this year, this article targets some issues of greatest relevance to our applicants, certificants, and vendors in a question-and-answer format. Additional information about all of these topics is available at http://www.bcia.org.
Platelet function testing in clinical diagnostics
Authors: Rechner A. R. 
Published: December 2010

SummaryAlthough the utility of platelet function testing is still under debate, the necessity to inhibit platelets in patients suffering from cardiovascular and cerebrovascular disease is undoubted and well proven. The wide variety of available platelet function tests often using different methodologies, the apparent lack of standardization, and finally the emerging evidence on the clinical value of platelet function testing are resulting in a considerable uncertainty in the clinical practice, how to deal with the issue of platelet function testing. Platelet function testing might not only yield clinical benefits for the patients but also economical advantages by identifying the right drug at the right dose for the right patient.This article intends to provide an overview of the current platelet function tests such as light transmittance aggregometry, whole blood impedance aggregometry, the PFA-1001 system, the VerifyNow2 system, flow cytometry, as well as other promising technologies like Plateletworks3, IMPACT-R4, PADA, thromboelastography, and the mean platelet component (MPC), briefly addressing strengths, weaknesses and clinical utility of these tests.
LFBTS: Enhanced Multimodality MRI Fusion for Brain Tumor Segmentation With Limited Computational Resources
Authors: Hu Yuanjing , Huang Aibin 
Published: February 2025

ABSTRACTEfficient and accurate segmentation of brain tumors in multimodal magnetic resonance imaging (MRI) is crucial for clinical diagnosis and treatment planning. Traditional methods tend to concentrate solely on feature extraction from individual modalities, overlooking the substantial potential of multimodal feature fusion in enhancing segmentation performance. In this paper, we present a novel method that not only integrates salient features from different modalities strategically but also takes into account the constraints imposed by limited computational resources, ensuring both accuracy and efficiency. Two key modules, the attention‐guided cross‐modality fusion module (ACFM) and the hierarchical asymmetric convolution module (HACM), were designed to leverage the distinct modalities and the varying information focuses found within different dimensions. The ACFM is based on a transformer framework, utilizing self‐attention and cross‐attention mechanisms. These mechanisms enable the capture of both local and global dependencies within and between different MRI modalities. This design allows for the effective fusion of complementary features from multiple modalities, thereby enhancing segmentation performance by leveraging the valuable information contained in each modality. Meanwhile, the HACM reduces computational complexity using a pseudo‐3D convolution approach. This approach breaks down 3D convolutions into components along the transverse and sagittal axes. Unlike traditional 2D convolutions, this method preserves essential spatial information across dimensions. It ensures accurate segmentation while maximizing efficiency by capitalizing on the varying focus of information in different spatial planes. This approach takes advantage of the varying information density in these dimensions, achieving a balance between accuracy and efficiency. Through extensive experiments on the BraTS2021 dataset, our proposed modality fusion‐based network under limited resources (LFBTS) achieves dice scores of 0.925, 0.911, and 0.886 for whole tumor (WT), tumor core (TC), and enhanced tumor (ET), respectively. These results outperform state‐of‐the‐art (SOTA) models and consistently demonstrate superiority over models developed in the preceding 2 years. This highlights the potential of our approach in advancing brain tumor segmentation and improving clinical decision‐making, particularly in settings with limited resources.